Latest News & Features
Americas
The US Food and Drug Administration has allowed the first US-based human trial of CRISPR, the gene-editing technology, to proceed. 17 October 2018
Americas
Nestlé Skin Health and Palette Life Sciences have entered into a global licensing agreement intended to improve outcomes for patients with urological and colorectal disorders. 17 October 2018
Americas
After spending four years at Hughes Hubbard & Reed, Stephen Rabinowitz has joined Dechert’s New York office as a partner. 17 October 2018
Big Pharma
The European Commission’s proposed export waiver for supplementary protection certificates has exposed a number of likely flaws which have not gone down well with patent owners. LSIPR reports. 17 October 2018
Big Pharma
The case of Actavis v Eli Lilly introduced “a real change in the law” and the way in which it addresses the doctrine of equivalence, according to Douglas Drysdale, partner at HGF in Glasgow, UK. 16 October 2018
Biotechnology
ERS Genomics, the company providing access to CRISPR/Cas9 IP owned by Emmanuelle Charpentier, has signed a licensing deal with synthetic biology startup Syngulon. 16 October 2018
Americas
The US Court of Appeals for the Federal Circuit has upheld two decisions that said patents relating to the dosage of Teva’s Copaxone 40mg/mL treatment are invalid. 15 October 2018
Americas
Nestlé’s Skin Health unit has been accused of infringing patents and misappropriating trade secrets relating to neurotoxin and derma filler injections. 15 October 2018
Americas
Samsung and HP are just two technology companies that have diversified and invested in the life sciences industry. What impact will this type of activity have on the sector and will it be beneficial in the long run? LSIPR finds out. 15 October 2018
Americas
AbbVie has announced yet another settlement relating to litigation over Humira, a drug used to treat multiple types of arthritis as well as psoriasis. 12 October 2018